Skip to main content
Clinical Trials/NCT06720272
NCT06720272
Recruiting
N/A

Effectiveness of an Integrated Program for the Prevention of Rheumatic Heart Disease in Endemic Regions: a Stepped Wedge Cluster Randomized Trial

Thomas Pilgrim0 sites6,000 target enrollmentDecember 15, 2024

Overview

Phase
N/A
Intervention
Not specified
Conditions
Rheumatic Heart Disease in Children
Sponsor
Thomas Pilgrim
Enrollment
6000
Primary Endpoint
Rheumatic heart disease
Status
Recruiting
Last Updated
3 months ago

Overview

Brief Summary

The overall objective of the PREVENT trial is to evaluate the effectiveness of an integrated, school-based program for the prevention of rheumatic heart disease (RHD) in regions with an endemic pattern of RHD.

We conduct a stepped wedge cluster randomized trial in randomly selected schools in Nepal and Zambia.

The intervention will be delivered at the level of the school and consists in the introduction of a dedicated school-nurse program providing health care through education about RHD, assessment, intervention, and follow-up of GABHS pharyngitis, and facilitation of secondary antibiotic prophylaxis for children with RHD.

Registry
clinicaltrials.gov
Start Date
December 15, 2024
End Date
February 1, 2028
Last Updated
3 months ago
Study Type
Interventional
Study Design
Sequential
Sex
All

Investigators

Sponsor
Thomas Pilgrim
Responsible Party
Sponsor Investigator
Principal Investigator

Thomas Pilgrim

MD, MSc

Insel Gruppe AG, University Hospital Bern

Eligibility Criteria

Inclusion Criteria

  • \- Children aged 5-16 years

Exclusion Criteria

  • Children / primary caregivers not providing informed consent to participate
  • Children not attending one of the selected schools

Outcomes

Primary Outcomes

Rheumatic heart disease

Time Frame: The endpoint will be assessed after a minimum of 1 and a maximum of 3 years after introduction of the school nurse program.

The primary outcome of the study will be the reduction in prevalence of rheumatic heart disease according to WHF criteria 2023 as assessed by systematic echocardiographic screening.

Similar Trials